Vaxcyte, Inc. Logo

Vaxcyte, Inc.

A clinical-stage company developing broad-spectrum vaccines for bacterial infectious diseases.

PCVX | US

Overview

Corporate Details

ISIN(s):
US92243G1085
LEI:
Country:
United States of America
Address:
825 INDUSTRIAL ROAD, STE. 300, 94070 SAN CARLOS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vaxcyte, Inc. is a clinical-stage vaccine company focused on preventing and treating bacterial infectious diseases. The company utilizes its proprietary cell-free protein synthesis platform, along with advanced chemistry and modern synthetic techniques, to engineer high-fidelity, broad-spectrum vaccines. Its lead candidates are VAX-24 and VAX-31, next-generation pneumococcal conjugate vaccines (PCVs) designed to offer broader protection against invasive pneumococcal disease, particularly for young children and older adults. Vaxcyte's pipeline also includes early-stage development programs for vaccines targeting Group A Strep and Shigella, aiming to set a new standard of care in bacterial disease prevention.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Vaxcyte, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vaxcyte, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vaxcyte, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR
ESSA Pharma Inc. Logo
Develops novel small molecule drugs to treat castration-resistant prostate cancer.
United States of America
EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
United States of America
ESLA
Eton Pharmaceuticals, Inc. Logo
Develops and commercializes innovative treatments for rare pediatric diseases.
United States of America
ETON
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea
206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Developing targeted, extended-release therapies for GI and musculoskeletal diseases.
United States of America
EPRX
EuroAPI Logo
Global manufacturer of APIs and CDMO services for human and animal health partners worldwide.
France
EAPI

Talk to a Data Expert

Have a question? We'll get back to you promptly.